Belantamab plus VRd led to promising outcomes in newly diagnosed transplant-eligible myeloma, study results showed.

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

Chlorhexidine dressings, along with proper patient education, are key in preventing central line-associated blood stream infections in patients with cancer.

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...